NeuroOne Medical Technologies Corporation has issued a corporate update highlighting accelerating commercial momentum and significant pipeline advancement across multiple neurological markets. The company reported its strongest quarter to date for its OneRF ablation system in brain procedures during fiscal Q1 2026, with nearly 50% of all ablations performed since the system's 2024 introduction occurring in that single quarter alone.
The company's technology platform is now advancing across three new market opportunities that each represent potential addressable markets exceeding $1 billion annually in the United States. These include drug delivery applications for conditions like glioblastoma, basivertebral nerve ablation for chronic low back pain, and spinal cord stimulation for pain management. NeuroOne's strategy leverages its existing FDA-cleared technology to efficiently develop differentiated products for these large markets.
Commercial progress is evident across multiple fronts. Following FDA 510(k) clearance last August for its trigeminal nerve ablation system, NeuroOne has completed nine cases across three centers, with all patients reportedly pain-free. The company is evaluating both direct commercialization and strategic licensing partnerships for this technology, which addresses trigeminal neuralgia affecting approximately 150,000 new patients annually in the United States.
The company's drug delivery program is now six months ahead of its original development schedule, targeting commercial readiness for investigational clinical or animal studies by the end of Q3 fiscal 2026. Initial focus areas include glioblastoma and gene and cell-based therapies. NeuroOne is establishing a physician advisory board and remains in active discussions with two potential partners for this program.
For business leaders and investors in medical technology, NeuroOne's platform approach demonstrates how a single technology foundation can be adapted to address multiple high-value clinical challenges. The company's partnership with Zimmer Biomet provides national reach without corresponding SG&A burden, while its growing intellectual property portfolio now includes 13 U.S. patents issued or pending plus four internationally.
Financially, NeuroOne maintains a strong position with zero debt, $3.6 million in cash and cash equivalents, and $6.8 million in working capital as of December 31, 2025. The company is guiding to at least $10.5 million in product revenue for fiscal year 2026, representing a minimum 17% increase over fiscal year 2025. This guidance does not include potential contributions from the recently cleared trigeminal nerve ablation system or potential non-dilutive cash from active partnership discussions.
The broader implications for the neurological device market are significant. NeuroOne's progress in basivertebral nerve ablation comes as this category gains validation through major transactions like Boston Scientific's acquisition of Relievant Medsystems for approximately $850 million upfront. The category has also attracted new product launches from companies such as Stryker, further expanding the long-term market opportunity.
For technology executives monitoring medical innovation, NeuroOne's platform demonstrates how capital-efficient development can target multiple billion-dollar markets simultaneously. The company's spinal cord stimulation program has initiated a six-month animal study in preparation for first-in-man studies, with potential strategic partners engaged in diligence discussions to accelerate commercialization.
NeuroOne's operational discipline is reflected in declining SG&A expenses and growing gross margins, with product gross margin reaching 54.2% in Q1 fiscal 2026. The company's diversified approach across brain, pain, and advanced drug delivery markets positions it to capture value across multiple neurological treatment paradigms as healthcare systems increasingly seek minimally invasive solutions that improve patient outcomes while reducing costs.
